| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/11/2009 | CA2707444A1 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| 06/11/2009 | CA2707308A1 Ido inhibitors |
| 06/11/2009 | CA2707299A1 Use of rr/sr-ractopamine |
| 06/11/2009 | CA2707248A1 New compounds ii |
| 06/11/2009 | CA2707192A1 Antimelancholic medicine prepared with jujube camp materials |
| 06/11/2009 | CA2707060A1 Polysaccharide gel compositions and methods for sustained delivery of drugs |
| 06/11/2009 | CA2707046A1 Small molecule myristate inhibitors of bcr-abl and methods of use |
| 06/11/2009 | CA2706990A1 Isoxazolo-pyrazine derivatives |
| 06/11/2009 | CA2706933A1 Nanoparticles of therapeutic agents having low water solubility |
| 06/11/2009 | CA2706923A1 Intravesical compositions with valrubicin for the treatment of bladder cancer |
| 06/11/2009 | CA2706920A1 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| 06/11/2009 | CA2706903A1 Dibenzoazepine and dibenzooxazepine trpa1 agonists |
| 06/11/2009 | CA2706898A1 Mequitazine for treating or preventing pathologies involving histamine h4 receptors |
| 06/11/2009 | CA2706883A1 Methods of treating copd |
| 06/11/2009 | CA2706880A1 Polysaccharide gel formulation |
| 06/11/2009 | CA2706879A1 Substituted cyclopentanes having prostaglandin activity |
| 06/11/2009 | CA2706821A1 Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome |
| 06/11/2009 | CA2706727A1 Compositions and methods for treating lysosomal disorders |
| 06/11/2009 | CA2706651A1 Tryptamine sulfonamides as 5-ht6 antagonists |
| 06/11/2009 | CA2706632A1 Substituted 2-naphthoic acids as antagonists of gpr105 activity |
| 06/11/2009 | CA2706420A1 Compounds for therapy and diagnosis |
| 06/11/2009 | CA2706155A1 Amide compounds as boosters of antivirals |
| 06/11/2009 | CA2705780A1 Periodontal bacterial growth inhibitor, oral hygiene product, and food and drink |
| 06/11/2009 | CA2705722A1 Organic compounds |
| 06/11/2009 | CA2705461A1 Novel vaccines against multiple subtypes of influenza virus |
| 06/11/2009 | CA2704266A1 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| 06/11/2009 | CA2701071A1 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| 06/10/2009 | EP2068152A1 c-Kit as a novel target for the treatment of pain |
| 06/10/2009 | EP2067862A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/10/2009 | EP2067784A2 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivates as anti-flammatory agents |
| 06/10/2009 | EP2067781A1 Agent for improving insulin resistance |
| 06/10/2009 | EP2067780A1 Ergoline derivatives as selective radical scavengers for neurons |
| 06/10/2009 | EP2067779A1 Tiotropium salts, method for their production and medicinal formulas containing them |
| 06/10/2009 | EP2067777A1 Oxepin derivative |
| 06/10/2009 | EP2067776A1 Piperidine compounds and pharmaceutical compositions containing them |
| 06/10/2009 | EP2067775A1 Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors |
| 06/10/2009 | EP2067772A2 Dibenzo [b,f] azepine intermediates and their preparation |
| 06/10/2009 | EP2067771A1 Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds |
| 06/10/2009 | EP2067487A2 Immunomodulatory formulations and methods for use thereof |
| 06/10/2009 | EP2067486A1 Use of CD23 antagonists for the treatment of neoplastic disorders |
| 06/10/2009 | EP2067480A1 Musclin receptor and use thereof |
| 06/10/2009 | EP2067477A1 New use of ginsenoside compound-k in manufacturing medicaments |
| 06/10/2009 | EP2067476A1 The application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the manufacture of a medicament for the treatment of inflammatory bowel disease |
| 06/10/2009 | EP2067475A1 Tacrolimus sustained-release preparation |
| 06/10/2009 | EP2067474A1 Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate |
| 06/10/2009 | EP2067473A2 Medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts |
| 06/10/2009 | EP2067472A1 Compositions and methods for the diagnosis and treatment of tumor |
| 06/10/2009 | EP2067471A1 Oral pharmaceutical dosage forms |
| 06/10/2009 | EP2067470A1 Pharmaceutical compositions containing valsartan and process for its preparation |
| 06/10/2009 | EP2067469A1 Chewable formulations |
| 06/10/2009 | EP2067406A1 Ubiquinol-enriched fat-containing dairy products |
| 06/10/2009 | EP2066800A2 Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation |
| 06/10/2009 | EP2066700A1 Dextran functionalized with hydrophobic amino acids |
| 06/10/2009 | EP2066685A2 Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| 06/10/2009 | EP2066683A1 Derivatives of 5-thioxylopyranose and use of same for treatment |
| 06/10/2009 | EP2066682A2 Crystalline forms of valrubicin and processes for their preparation |
| 06/10/2009 | EP2066681A1 New derivatives of 5-thioxilopyranose |
| 06/10/2009 | EP2066679A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 06/10/2009 | EP2066678A1 Spiro antibiotic derivatives |
| 06/10/2009 | EP2066677A1 Pyridooxazepine progesteron receptor modulators |
| 06/10/2009 | EP2066676A1 HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| 06/10/2009 | EP2066674A1 Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents |
| 06/10/2009 | EP2066673A2 Tricyclic compounds and its use as tyrosine kinase modulators |
| 06/10/2009 | EP2066672A1 An improved process for the preparation of temozolomide and analogs |
| 06/10/2009 | EP2066669A1 Adenosine derivatives as a2a receptor agonists |
| 06/10/2009 | EP2066668A1 Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
| 06/10/2009 | EP2066666A1 Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivates as stimulators of guanylate cyclase for cardiovascular disorders |
| 06/10/2009 | EP2066664A1 Heterocyclic organic compounds |
| 06/10/2009 | EP2066663A1 Heterocyclic fxr binding compounds |
| 06/10/2009 | EP2066662A2 Serine hydrolase inhibitors |
| 06/10/2009 | EP2066660A2 Therapeutic lactams |
| 06/10/2009 | EP2066658A1 Pyridine- and quinoline-pyrimidine-derivatives |
| 06/10/2009 | EP2066657A1 Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands |
| 06/10/2009 | EP2066656A2 5-substituted quinazolinone derivatives as antitumor agents |
| 06/10/2009 | EP2066655A2 Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
| 06/10/2009 | EP2066654A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as ep2 receptor modulators |
| 06/10/2009 | EP2066653A1 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents |
| 06/10/2009 | EP2066649A1 Process for the preparation of amorphous and crystalline forms of candesartan cilexetil using column chromatography |
| 06/10/2009 | EP2066648A1 Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments |
| 06/10/2009 | EP2066647A1 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors |
| 06/10/2009 | EP2066645A2 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
| 06/10/2009 | EP2066644A2 Salts of rosuvastatin and processes for their preparation |
| 06/10/2009 | EP2066642A1 Soluble epoxide hydrolase inhibitors |
| 06/10/2009 | EP2066641A1 Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 06/10/2009 | EP2066640A2 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives |
| 06/10/2009 | EP2066639A1 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist |
| 06/10/2009 | EP2066638A1 Process for the purification of montelukast |
| 06/10/2009 | EP2066637A1 Novel substituted bipyridine derivatives and their use as adenosine receptor ligands |
| 06/10/2009 | EP2066636A1 5-phenyl-nicotinamide derivatives |
| 06/10/2009 | EP2066635A2 2-phenoxy nicotine acid derivative and use thereof |
| 06/10/2009 | EP2066634A1 4-phenoxy-nicotine acid derivatives and use thereof as ppar-modulators |
| 06/10/2009 | EP2066633A1 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| 06/10/2009 | EP2066632A1 Benzophenone derivatives useful for inhibiting formation of microtubule |
| 06/10/2009 | EP2066630A1 Piperidine derivatives |
| 06/10/2009 | EP2066628A1 2-phenyl-indoles as prostaglandin d2 receptor antagonists |
| 06/10/2009 | EP2066627A1 Novel minor groove binders |
| 06/10/2009 | EP2066626A1 Azetidine derivatives as muscarinic receptor antagonists |
| 06/10/2009 | EP2066621A1 Synthesis, polymorphs, and pharmaceutical formulation of a faah inhibitor |
| 06/10/2009 | EP2066619A2 Soluble epoxide hydrolase inhibitors |
| 06/10/2009 | EP2066355A2 Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |